Qlaris Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-08-01
- Employees
- 1
- Market Cap
- -
- Website
- http://qlaris.bio
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
Phase 2
Completed
- Conditions
- Ocular Hypertension (OHT)GlaucomaOpen-angle Glaucoma (OAG)
- Interventions
- Drug: QLS-111, 0.015%Drug: QLS-111 vehicle ophthalmic solutionDrug: QLS-111, 0.030%Drug: QLS-111, 0.075%
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06249152
- Locations
- 🇺🇸
Berkeley Eye Center, Houston, Texas, United States
Study of an Investigational Product, QLS-111, Provided As an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
Phase 2
Not yet recruiting
- Conditions
- Normal Tension Glaucoma (NTG)Low-Tension Glaucoma, Unspecified EyeLow-Tension Glaucoma, BilateralGlaucoma
- Interventions
- Drug: QLS-111 ophthalmic solution (0.015%)Drug: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06030193
- Locations
- 🇰🇷
To be determined, Seoul, Korea, Republic of
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
Phase 2
Completed
- Conditions
- Primary Open Angle Glaucoma of Both EyesPrimary Open Angle Glaucoma (POAG)Ocular Hypertension (OHT)Primary Open-Angle Glaucoma, Unspecified Eye
- Interventions
- Other: QLS-111 ophthalmic vehicle solution
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT06016972
- Locations
- 🇺🇸
Coastal Research Associates, LLC, Roswell, Georgia, United States
Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)
Phase 2
Completed
- Conditions
- Sturge-Weber SyndromeGlaucomaOcular Hypertension
- Interventions
- Drug: QLS-101 ophthalmic solution, 2.0 %
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05495269
- Locations
- 🇺🇸
Duke Eye Center, Durham, North Carolina, United States
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
Phase 2
Completed
- Conditions
- Sturge-Weber Syndrome (SWS)GlaucomaGlaucoma CongenitalOcular Hypertension
- Interventions
- Drug: QLS-101ophthalmic solution 1%Drug: QLS-101ophthalmic solution 2%
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT04947124
- Locations
- 🇺🇸
Duke Eye Center, Durham, North Carolina, United States
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
Phase 2
Completed
- Conditions
- Normal Tension Glaucoma (NTG)
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04857827
- Locations
- 🇺🇸
Vance Thompson Vision, Sioux Falls, South Dakota, United States
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
Phase 2
Completed
- Conditions
- Ocular HypertensionPrimary Open Angle Glaucoma
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT04830397
- Locations
- 🇺🇸
Dixon Eye Care, Albany, Georgia, United States
© Copyright 2025. All Rights Reserved by MedPath